Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alector Inc (NQ: ALEC )

5.730 +0.240 (+4.37%)
Streaming Delayed Price Updated: 11:40 AM EST, Dec 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 83,081
Open 5.550
Bid (Size) 5.730 (2)
Ask (Size) 5.750 (26)
Prev. Close 5.490
Today's Range 5.480 - 5.750
52wk Range 3.660 - 9.860
Shares Outstanding 83,351,778
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These biotechs targeting multiple neurodegenerative diseases
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market. 
Via MarketBeat
Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs
Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively 
From Alector, Inc.
Via GlobeNewswire

Performance

YTD
-37.03%
-37.03%
1 Month
+4.75%
+4.75%
3 Month
+10.30%
+10.30%
6 Month
-22.78%
-22.78%
1 Year
-33.83%
-33.83%

More News

Read More
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Analyst Expectations for Alector's Future
Via Benzinga
Expert Ratings for Alector
Via Benzinga
Preview: Alector's Earnings
Via Benzinga
Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Alector to Participate in the Stifel Healthcare Conference
From Alector, Inc.
Via GlobeNewswire
Alector Reports Third Quarter 2023 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
From Alector, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Via Benzinga
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Alibaba, Standard Lithium, Anterix And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2023
Via Benzinga
How The Same Treatments May Work For Multiple Neurodegenerative Diseases
Via Talk Markets
Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
From Alector, Inc.
Via GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why ResMed Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Alector Reports Second Quarter 2023 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Alector to Host Mid-Year Earnings Conference Call
From Alector, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.